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Abstract
Introduction: The term atypical pituitary adenoma (APA) was revised in the 2004 World Health Organization (WHO)
classification of pituitary tumors. However, two of the four parameters required for the diagnosis of APAs were
formulated rather vaguely (i.e., “extensive” nuclear staining for p53; “elevated” mitotic index). Based on a case-control
study using a representative cohort of typical pituitary adenomas and APAs selected from the German Pituitary
Tumor Registry, we aimed to obtain reliable cut-off values for both p53 and the mitotic index. In addition, we
analyzed the impact of all four individual parameters (invasiveness, Ki67-index, p53, mitotic index) on the selectivity
for differentiating both adenoma subtypes.
Methods: Of the 308 patients included in the study, 98 were diagnosed as APAs (incidence 2.9 %) and 10 patients
suffered from a pituitary carcinoma (incidence 0.2 %). As a control group, we selected 200 group matched
patients with typical pituitary adenomas (TPAs). Cut-off values were attained using ROC analysis.
Results: We determined significant threshold values for p53 (≥2 %; AUC: 0.94) and the mitotic index (≥2 mitosis
within 10 high power fields; AUC: 0.89). The most reliable individual marker for differentiating TPAs and APAs was a
Ki-67-labeling index≥ 4 % (AUC: 0.98). Using logistic regression analysis (LRA) we were able to show that all four criteria
(Ki-67 (p < 0.001); OR 5.2// p53 (p < 0.001); OR 3.1// mitotic index (p < 0.001); OR 2.1// invasiveness (p < 0.001); OR 8.2))
were significant for the group of APAs. Furthermore, we describe the presence of nucleoli as a new favorable
parameter for TPAs (p = 0.008; OR: 0.4; CI95 %: 0.18; 0.77).
Conclusions: Here we present a proposed rectification of the current WHO classification of pituitary tumors
describing an additional marker for TPA and specific threshold values for p53 and the mitotic index. This will
greatly help in the reliable diagnosis of APAs and facilitate further studies to ascertain the prognostic relevance of
this categorization.
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Introduction
Pituitary adenomas (PAs) are the most common benign neo-
plasms in the sellar region, occurring in 10 % [1] to 20 % [2,
3] of the general population. In most cases, they represent
slowly growing, clinically nonfunctioning tumors developing
from adenohypophysial cells [4]. Earlier classification systems
were based on tumor size (microadenomas <10 mm vs.
macroadenomas >10 mm) and basic staining characteristics
(acidophilic, basophilic, chromophobic). Today, histopatho-
logical analysis of the hormone expression profile using im-
munohistochemistry allows for the differentiation of several
subtypes and variants (e.g., GH, PRL, ACTH, TSH, FSH, LH,
plurihormonal, null cell adenomas, densely and sparsely
granulated tumors) [5, 6]. For prognostic purpose, the
current 2004 WHO classification of tumors of endocrine or-
gans revised diagnostic criteria for the group of atypical pitu-
itary adenomas (APAs). The aim was to identify tumors with
histomorphological signs of intermediate malignancy, most
likely indicating uncertain clinical and biological behavior.
Furthermore, APAs were thought to be the precursor lesion
of the very rare group of pituitary carcinomas (PCA), repre-
senting the only malignant primary sellar tumor entity
(0.2 %) which per definition featured systemic and/or cere-
brospinal metastases. Histological and immunohistochemical
criteria were defined for the diagnosis of APA: 1.) Invasive
tumor growth; 2.) Ki-67 labeling index (LI) greater than 3 %;
3.) Elevated mitotic activity; 4.) Extensive nuclear staining for
p53 [7, 5] (Fig. 1). In comparison to existing diagnostic cri-
teria for other primary brain tumors with intermediate ma-
lignancy such as atypical meningiomas, some of the criteria
(especially p53 and the mitotic index), were formulated ra-
ther vaguely. This may be one explanation for the different
frequencies of APAs published in several larger series since
2004 [8, 6, 9]. To address this important issue and to increase
diagnostic clarity and reproducibility in routine diagnostic
work, we initiated a case-control study using a large cohort
of 308 patients selected from the German Pituitary Tumor
Registry. Specific to this registry, all samples were analyzed
by only two different pathologists with a long-standing ex-
pertise in the investigation of pituitary tumors (WS and RB).
Cases sent to the register were documented and the initial
diagnoses were reviewed using new slides and stainings. Two
great benefits of this approach are the avoidance of inter-
observer heterogeneity and the standardization of both tech-
nical and analytical processes. A reliable and reproducible
diagnosis is the basis for initiating further studies to clarify




Patients were identified from the German Pituitary Tumor
Registry in cooperation with members of the German pituit-
ary working group (see Acknowledgements). Pathological
reports from a total of N = 4232 patients documented
between 2005 and 2012 were analyzed. Therefore, 4101
tumors were diagnosed as typical pituitary adenomas
(TPAs; 96.9 %) and 121 as atypical pituitary adenomas
(APAs; 2.9 %). A group of ten patients with a pituitary car-
cinoma (PCA; 0.2 %) diagnosed between 1995 and 2011
was also included. The inclusion criteria for statistical ana-
lysis was the presence of a minimum of three of the pa-
rameters suggested by the WHO for the diagnosis of
APAs: p53 immunoreactivity, MIB-1 (Ki-67) index, mitotic
activity and invasiveness. Each marker was analyzed for
each group separately. Twenty three APAs had to be ex-
cluded due to incomplete clinical and/or histopathological
data or resulting from the absence of two or more of the
aforementioned criteria. However, a total of 98 cases did
meet the requirements and were finally selected for the
study. Moreover, 200 group matched patients (in terms of
age, sex and adenoma subtype) withTPAs served as a con-
trol group [10]. Overall we analyzed a cohort of 98 APAs,
10 PCAs and 200 group matched TPAs (Table 1).
Patient age at surgery, gender, as well as histopatho-
logical tumor parameters such as immunohistochemical
hormone expression (GH, PRL, ACTH, TSH, FSH, LH,
α-subunit), protein S100 expression, presence of nucleoli
and invasiveness, mitotic activity and expression of the
cell cycle markers p53 and Ki-67 were recorded (Table 1
and Table 3). All of the cases were stained twice, once
by the initial pathologist and once by the registry lab
and the number of positive cells was determined in 10
representative high power fields during the initial diag-
nosis and the re-evaluation process. Only nuclei with a
distinct nuclear expression were taken into account
(see Fig. 1). In cases of inter-observer heterogeneity, a
second and third evaluation were conducted. Verifica-
tion of tumor invasion in surrounding anatomical struc-
tures (e.g., meninges, bone, brain tissue, sphenoidal sinus)
was evaluated using either surgical reports, the preopera-
tive MRI samples or confirmed by clear histology.
Tumor specimens and staining results
All specimens were routinely formalin fixed, embedded in
paraffin and stained with hematoxylin-eosin and PAS-
reaction. The following immunostainings were performed
for each sample: anti-GH (monoclonal), Novocastra,
Newcastle upon Tyne, UK, 1:1000; anti-Prolactin
(monoclonal), Zytomed, Berlin, Germany, 1:12000,
anti-ACTH (polyclonal), Zytomed, Berlin, Germany,
1:30; anti-TSH (monoclonal), Immunotech, Marseille,
France, 1:5000, anti-FSH (monoclonal), Immunotech,
Marseille, France, 1:20000, anti-LH (monoclonal)
Immunotech, Marseille, France, 1:2500, anti-alpha-
subunit (monoclonal), Immunotech, Marseille, France,
1:1500, anti-Ki67/MiB-1 (monoclonal), Zytomed, Berlin,
Germany, 1:750, anti-p53 (monoclonal) Novocastra,
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Newcastle upon Tyne, UK, 1:150, anti-S100-protein
(polyclonal) Dako, 1:1250, and for differentiation of
sparsely and densely granulated GH cell adenomas anti-
Keratin/KL1 (monoclonal), Immunotech, Marseille, France,
undiluted.
Both Ki-67 labeling index (LI) and the number of
p53 immunopositive nuclei were independently, semi-
quantitatively assessed by two experienced patholo-
gists (WS and RB) within hot spot areas of the
tumor samples. Mitotic figures were retrospectively
Table 1 Histological tumor classification
Tumour subtypes Study groups
TPAs APAs PCAs Total
Number % Number % Number % Number %
Densely granulated GH-cell adenomas 5 2.5 % 3 3.1 % 0 0.0 % 8 2.6 %
Sparsely granulated GH-cell adenomas 16 8.0 % 11 11.2 % 1 10.0 % 28 9.1 %
Mixed GH/PRL-cell adenomas 9 4.5 % 6 6.1 % 0 0.0 % 15 4.9 %
PRL-cell adenomas 64 32.0 % 32 32.7 % 2 20.0 % 98 31.8 %
Densely granulated ACTH-cell adenomas 19 9.5 % 8 8.2 % 0 0.0 % 27 8.8 %
Sparsely granulated ACTH-cell adenomas 49 24.5 % 20 20.4 % 0 0.0 % 69 22.4 %
ACTH-cell adenomas, NOS 0 0.0 % 0 0.0 % 7 70.0 % 7 2.3 %
TSH-cell adenomas 3 1.5 % 2 2.0 % 0 0.0 % 5 1.6 %
FSH/LH-cell adenomas 10 5.0 % 5 5.1 % 0 0.0 % 15 4.9 %
Null cell adenomas 25 12.5 % 11 11.2 % 0 0.0 % 36 11.7 %
Total 200 100 % 98 100 % 10 100 % 308 100 %
The histological classification of each tumor analyzed in the groups of typical pituitary adenomas (TPA), atypical pituitary adenomas (APA) and pituitary
carcinomas (PCA) is shown in detail. NOS not otherwise specified
GH growth hormone, PRL prolactin, ACTH adrenocorticotrophic hormone, TSH thyroid-stimulating hormone, FSH follicle-stimulating hormone, LH
luteinizing hormone
Fig. 1 Diagnostic criteria for atypical pituitary adenomas. An example of an atypical pituitary adenoma (ACTH-cell adenoma) with several
mitotic figures (Arrows in a) in one HPF (HE staining, magnification 400x), infiltration of surrounding meninges (Arrows in b, HE staining,
magnification 100x), Ki67 index >4 % (c, magnification 400x) and strong nuclear p53 expression in >3 % of cells (d, magnification 400x;
Arrows: negative endothelial cells indicating antibody specificity)
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quantified within ten representative high power fields (HPF of
0.30 mm2, 400 × magnification) using hematoxylin and eosin
stained (H&E) sections by two investigators (CM and RB),
in all samples evaluable (APAs n = 78, TPAs n = 151 and
PCAs n = 4). The existence of nucleoli was evaluated in the
same way in a cohort of 77 APAs, 148 controls and 7 PCAs.
Study design and statistical analysis
In order to show strength of influence, we applied logis-
tic regression analysis (LRA) to the combination of the
currently proposed markers for atypia independently
(Ki-67 LI, mitotic rate, p53 expression, invasiveness; ac-
cording to the WHO classification system of endocrine
tumors) in a large cohort of TPAs (“controls”), APAs
(“cases”) and PCAs (“cases”) [11]. Receiver operator
curve (ROC) analyses were performed for each param-
eter to find reliable cut-off values, and the Youden index,
as well as area under curve (AUC) served as quality con-
trol [12, 13]. The AUC values were interpreted as fol-
lows: 0.5–0.7 =minimal; 0.7–0.9 =moderate; >0.9 = high
discriminatory power [14, 13]. We compared the groups
of APAs and PCAs versus Controls as well as PCAs and
APAs respectively to evaluate the individual impact and
significance of each marker. Three additional markers
(α-subunit, protein S100, nucleoli) were studied in sub-
groups (APA/TPA) and their properties were analyzed
using LRA to investigate their relevance as diagnostic
factors on their own. Furthermore, additional odds ratios
(OR) were calculated for each parameter. “An odds ratio
(OR) is a measure of association between an exposure
and an outcome. The OR represents the probability that
an outcome will occur given a particular exposure, com-
pared to the odds of the outcome occurring in the ab-
sence of that exposure. Odds ratios are most commonly
used in case-control studies (…) [15].” The pseudo-
coefficient of determination (Nagelkerkes R2) was used
to measure the predictive power of the model [16, 17].
The correlations between individual metric parameters
(Ki-67, p53, mitosis) were analyzed by Spearman’s rank
correlation. In case of the dichotomous parameter inva-
siveness, the point-biserial correlation coefficient was
assessed [18]. Additionally, the correlation between the
subgroups and metric parameters were also calculated
using the point-biserial method. The phi coefficients
were used for dichotomous (invasiveness, nucleoli)
and ordinal coded data (α-subunit, protein S100) re-
lated to the subgroups. With respect to ordinal coded
data, the results were verified using Cramers V [18].
The accuracy was calculated in common way accuracy ¼ð
number of true positivesþnumber of true negatives
number of true positivesþfalse positivesþfalse negativesþtrue negativesÞ [19].
P-values less than 5 % were viewed as being statistically
significant and for all statistical analyses IBM SPSS Statis-
tics 21 software was used.
Results
Clinical characteristics
Out of the 308 patients included in the study, 98 were
diagnosed as atypical pituitary adenomas (APAs). A typ-
ical example is presented in Fig. 1, showing mitotic fig-
ure, high levels of Mib-1 and p53, as well as invasion of
surrounding structures. This group was composed of
51 men (52 %, mean age at surgery = 42 years, range
16–78 years) and 46 women (47 %, mean age at surgery =
46 years, range 13–83 years). In one case, the gender was
not documented. The tumors correspond to thirteen
different adenoma subtypes (including sparsely and
densely granulated variants; Table 1) of which the lar-
gest group were diagnosed as prolactin cell adenomas
(n = 32; 32.7 %) followed by: ACTH-cell adenomas (n =
28; 28.6 %), GH-cell adenomas (n = 14; 14.3 %), null-
cell adenomas (n = 11; 11.2 %), mixed GH/Prolactin cell
adenomas (n = 6; 6.1 %), FSH/LH-cell adenomas (n = 5;
5.1 %) and TSH-cell adenomas (n = 2; 2 %) 12 of these
cases (12.1 %) were relapses.
The case study group and the control group (n = 200
patients) had equivocal comparative values with regards
to age and gender. One particular patient is listed in
both, the case study group (surgery in 2009) and also in
the PCA group (relapse 2010), but this case was not ap-
plied for statistical analysis.
The group of patients with pituitary carcinomas
(PCAs) consists of six men (60 %; mean age 40; range
24–53 years) and four women (40 %; mean age 61; range
53–77years). Seven patients included in the study suf-
fered from an ACTH-cell carcinoma (70 %), two patients
had a PRL-cell carcinoma (20 %) and one patient a
sparsely granulated GH-cell carcinoma (10 %). Detailed
clinical data is summarized in Table 1.
ROC analysis
ROC analysis determined a cut-off ≥ 2 Mitoses in 10 HPF
for the number of mitoses. There was a range of 0–8 mi-
toses among the group of TPAs and a range of 0–41 in
the group of APAs respectively. Sensitivity was 90 % and
specificity 74 %. The quality of the diagnostic tests was de-
termined with a Youden index rating of 0.64 and an AUC
of 0.89 (Fig. 2a). Therefore, accuracy is up to 79 %. The
identified threshold value for the MIB-1 proliferation
index of ≥4 % was slightly higher than the current cut-off
value suggested by the WHO (>3 %). The spectrum of
Ki-67 LI for TPAs ranged from 0 to 6 % and for the
group of APAs between 1 and 50 %. Sensitivity was
95 % and specificity 97 %. The good quality of these
diagnostic tests was confirmed by the Youden index
value of 0.92 and the AUC of 0.98 (Fig. 2b). Accuracy
was scored at 96 %. A distinct nuclear staining in ≥ 2 %
of cells was found to be the best cut-off value for p53.
The span of the controls ranged from 0 to 10 % and
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from 0 to 60 % in the group of APAs. Sensitivity and
specificity were found at 85 % and 93 % respectively
(Youden index: 0.78). With an AUC of 0.94, a high dis-
criminatory power was evident (Fig. 2c). The accuracy
in this case was 90 %. The entire data is presented in
Table 2 and furthermore an overview of the average
values from mitosis, Ki-67 and p53 is shown in Table 3.
Reliability of markers
Using a binary logistic regression analysis (LRA), it was
verified that all four predictors (invasiveness, mitotic rate,
p53, Ki-67) significantly contributed to the definition of
the dependent variables (typical/atypical adenoma). An
error reduction (“pseudo-coefficients of determination”)
according to Nagelkerke’s R2 of 0.86 for Ki67, 0.69 for
p53, 0.53 for the number of mitosis and 0.22 for invasive-
ness was calculated, acknowledging the associated pre-
dictive power. Therefore, it can be said that the
existence of an APA increases by a factor of 8.2 (p < 0.001)
when an invasive growth pattern is present (Sensitivity
88 %, Specificity 53 %, Youden Index 0.41, Accuracy
64 %), by a factor of 5.2 (p < 0.001) per percentage point of
Fig. 2 Statistical analysis of the mitotic index, Ki-67 and p53 in the groups of TPA and APA. The Boxplot and Receiver operator curve (ROC) analysis
based on the mitotic index (=number of mitosis counted in 10 high power fields (HPF); 400x magnification; a) and the values of tumor cell nuclei
showing a distinct Ki-67 (b) and p53 (c) expression (%) in hot spot areas of the single tumor samples. The Y-axis is log scaled to figure out a clearer
illustration of the lower values. Single outliers are presented as circles. The range and distribution of the analyzed parameters Ki67, p53 and number of
mitotic figures in both subgroups (TPAs/APAs) is visualized using box plots. The boxes represent the 25th and the 75th percentiles, including
the median value as a dark horizontal bar
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Ki67 positive tumor cell nuclei, by a factor of 3.1 (p < 0.001)
with each percentage point of p53 immunopositive nuclei
and with a factor of 2.1 (p < 0.001) per every single mitosis
in 10 HPF (Table 2; Fig. 2 a, b, c).
Taking only into account the newly suggested Ki67
(≥4 %) and p53 (≥2 %) cut off values, it was possible to
correctly categorize 286/298 tumors (7 false pos. & 5 false
neg.) and 268/298 tumors (15 false pos. & 15 false neg.)
respectively. A combination of both parameters enabled
for the right diagnosis of 277/298 samples (21 false pos. &
0 false neg.). The correlation analysis showed that all four
parameters discussed were significant amongst themselves
as well as in relation to the subgroups (typical/atypical) on
the level 0.001. Only invasiveness and p53 were signifi-
cant on level 0.05 in relation to each other. A positive
correlation coefficient was detected in both models.
Statistical data is summarized in Additional file 1: Table
S1 and Additional file 2: Table S2.
Neither the correlation analysis nor the LRA showed
significant differences between the case study and the
control group with respect to protein S100 (p = 0.151,
rphi = 0.134; LRA: p = 0.269, R
2 = 0.006) and the α-subunit
(p = 0.138, rphi = 0.137; LRA: p = 0.955, R
2 = <0.001). How-
ever, both models showed significant differences be-
tween the two subgroups with regard to existence of
nucleoli (p = 0.006, rphi =−0.181; LRA: p = 0.008, R
2 = 0.04).
A low negative correlation coefficient was measured. It
must be noted that the presence of nucleoli reduced
the risk of an APA by a factor of only 0.4 (p = 0.008;
CI95 %: 0.18; 0.77, R2 = 0.04).
Pituitary carcinomas
Ten PCAs were compared to 40 TPAs of the control
group. The latter were selected on the basis of age, sex
and adenoma subtype. The cut-off values, which were de-
termined in the group of APA cases, were applied to the
parameters Ki-67, p53 and the mitotic index, without
prior ROC analysis due to the small number of samples
available. The overall incidence of PCAs in our series of
sellar tumors was 0.2 %. Point-biserial analysis showed
that Ki-67 (p < 0.001; rpb = 0.556), p53 (p < 0.001; rpb =
0.483) and the phi coefficient of invasiveness (p = 0.004;
rphi = 0.439) were significant at the 0.01 level in correl-
ation with both subgroups (PCA/TPA). A positive
correlation coefficient was detected in these cases.
The mitotic index reached no significant level (p = 0.097;
rpb = 0.266), but yet attained a sensitivity of 100 %. Only
four of ten PCAs could be reevaluated with respect to
the number of mitoses. Statistical data is summarized
in Additional file 1: Table S1.
The LRA showed that only the parameters Ki-67 (OR:
1.8) (p = 0.012; R2 = 0.41) and p53 (OR: 1.8) (p = 0.01; R2 =
0.44) were significant regressors, whereas number of mi-
tosis (p = 0.124; R2 = 0.11) and invasiveness (p = 0.998;
R2 = 0.36) failed this assumption. A sensitivity of 60 %
and a specificity of 93 % as well as an accuracy of 86 %
were obtained for p53 and Ki67. Due to matching 12
TPAs were not taken into account with regard to mi-
tosis (n = 4) and invasiveness (n = 8).
In contrast, another model showed neither signifi-
cant differences between PCAs (n = 10) and APAs (n = 20)
Table 3 Frequency of WHO criteria in the different tumor subtypes
Subgroups All Patients
TPAs APAs PCAs Total
N= Mean N= Mean N= Mean N= Mean
Mitotic index (in 10 HPF) 200 1 98 7 10 3 308 3
p53 pos. Nuclei (%) 200 1 98 8 10 8 308 3
Ki-67 pos. Nuclei (%) 200 1 98 9 10 7 308 4
Growth pattern Non invasive 77 - 8 - 0 - 85 -
Invasive 68 - 58 - 10 - 136 -
Overview of metric and dichotomous parameters analyzed in the subgroups of pituitary tumors analyzed
N number, HPF High power field, TPA typical pituitary adenomas, APA atypical pituitary adenomas, PCA pituitary carcinomas
Table 2 Statistical values of the main histomorphological parameters
Diagnostic Parameters
for APAs/TPAs
Cut-off Sensitivity Specitifity Youden-Index Accuracy in % AUC 95 % CI
of AUC
OR 95 % CI
of OR
P-value
Ki-67 pos. nuclei in % ≥4 0.95 0.97 0.92 96 0.98 [0.96; 1.0] 5.2 [3.43; 7.83] <0.001
P53 pos. nuclei in % ≥2 0.85 0.93 0.78 90 0.94 [0.90; 0.97] 3.1 [2.31; 4.04] <0.001
Mitotic Index in 10 HPF ≥2 0.90 0.74 0.64 79 0.89 [0.84; 0.93] 2.1 [1.70; 2.57] <0.001
Invasiveness Yes 0.88 0.53 0.41 64 - - 8.2 [3.66; 18.42] <0.001
The proposed threshold values for Ki-67, p53, number of mitotic figures in 10 HPF (high power fields) and the status of invasive tumor growth, to distinguish APA
and TPA are shown with their respective statistical values
OR odds ratio, AUC area under curve, CI confidence interval
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with respect to the markers Ki-67 (p = 0.223), p53 (p =
0.585), the mitotic index (p = 0.274) and invasiveness
(p > 0.999) featured in the LRA, nor in the point-biserial
correlation analysis with values of Ki-67 (p = 0.204), p53
(p = 0.594), mitotic index (p = 0.189) and the phi coeffi-
cient of invasiveness (p = 0.245). Statistical data is summa-
rized in Additional file 1: Table S1. Due to matching, six
APAs were not taken into account with regard to mitosis
(n = 2) and invasiveness (n = 4).
Discussion
The goal of this study was to further specify the vaguely
described histomorphological and immunohistochemical
parameters for the diagnosis of an atypical adenoma
(APA). Even though this diagnosis was introduced more
than ten years ago by the World Health Organization
(WHO), specific cut-off values for the criteria “elevated
mitotic index” and “extensive nuclear staining for p53
immunoreractivity” are still missing. Furthermore, we
tested the consistency of the four suggested criteria for
atypical tumor growth (i.e., Ki-67, invasiveness, number
of mitosis and p53 levels) [7, 20–24, 6, 25], comparing a
large cohort of typical pituitary adenomas (TPAs), APAs
and pituitary carcinomas (PCAs). All the tumor cases
were selected from the German Pituitary Tumor Regis-
try in Hamburg. During the time period examined
(2005–2012), APA reached an overall frequency of 2.9 %
(121/4231), a value which increased only slightly com-
pared to the frequency of 2.7 % (12/451) described in
2007 [6]. In line with previously published data from
2007, more than 84 % (n = 83/98) of APAs can be classi-
fied as either sparsely granulated prolactinomas, ACTH
secreting adenomas, growth hormone producing aden-
omas or null cell adenomas [6]. A study of Zada et al.
published in 2011 [8] showed a similar subtype distri-
bution within the group of APAs, but a clearly higher
occurrence of 14.9 % (n = 18/121). This was confirmed
by another group describing an incidence value of
8.9 % (n = 13/146), respectively [9]. These varying fre-
quencies may reflect the problems in using the existing
diagnostic criteria for APAs, irrespective of the experi-
ence of the pathologist. Thus the first important aspect
of the study presented here was to suggest reliable, re-
producible and easy to predict cut-off values for the mi-
totic rate and the p53 expression level.
Using ROC curve analysis, we defined a valid cut-off
value for the number of mitotic figures as ≥ 2 mitoses
per 10 HPF in APA cases. The quality of the chosen
threshold value is documented by a Youden index rating
of 0.64 and an AUC of 0.89, as well as a sensitivity of
90 % and a specificity of 74 %. Overall, this single par-
ameter allows a correct graduation in up to 79 % of
cases which indicates that it should not be used alone
when making a reliable diagnosis. Despite the difficulties
attempting to choose a correct cut-off value, the risk of
an APA increases by a factor of 2.1 (p < 0.001) per each
mitosis within 10 HPF (Table 3). In general, the number
of mitosis are easy to achieve although tissue shrinkage,
delayed fixation time and bleeding may cause problems
and should be taken into account [22].
Nuclear accumulation of p53 as a prognostic marker for
pituitary tumors is discussed controversially throughout
the literature. There are several studies featuring different
results with regard to its importance in the growth behav-
ior (aggressive/invasive) of adenomas [26–32, 21, 33–36].
Using our large cohort and the analytical, statistical and
technical methods as described, we propose using a
threshold value for p53 of ≥2 % of clearly immunoreactive
nuclei for the diagnosis of an APA. More than 93 % of the
control cases showed a lower expression (<2 %) (Table 3).
The very high specificity value (93 %) proves that p53 pro-
tein expression ≥2 % (Youden index 0.78) is an extremely
helpful and significant parameter. Nevertheless, even an
absolute negative staining result does not eliminate the
possibility of aggressive/invasive tumor growth, indicated
by a relatively low sensitivity (85 %). The good quality of
the p53 value, independent from the cut-off, is further
supported by the AUC (0.94). It must be taken into ac-
count that the immunohistochemical detection of p53 is
dependent upon on the antibody and the method used for
investigation [37].
In addition to describing detailed cut-off values for
p53 immunoreactivity and the number of mitotic figures,
we further analyzed the discriminatory power of the
existing Ki67 labeling index and an invasive tumor
growth pattern. The latter was propagated as a helpful
marker to distinguish TPAs from APAs and was already
mentioned in the previous WHO classification system
[5]. The importance of measuring the Ki-67 LI with re-
spect to invasiveness, progression and clinical character-
istics is highly controversial [38–46, 36, 47]. The varying
counting methods and antibodies used to determine the
K67 LI may be, in part, an explanation for the contra-
dictory results already published [42, 47]. Although both
levels mathematically represent the same group of sam-
ples (>3 % = ≥4 %), we would prefer using a cut-off value
for Ki-67 ≥ 4 % for our cohort as this has the better dis-
criminatory power and is more precisely defined
(Table 3). A very high specificity (97 %) and sensitivity
(95 %) indicates indeed that the proliferation index is a
very good and reliable diagnostic tool (Youden index
0.92) that provides important results for the diagnosis of
an APA. In comparison to p53 immunoreactivity (0.94)
and the mitotic index (0.89), the Ki-67 LI had the
highest AUC (0.98), suggesting it to be the best single
parameter for the diagnosis of APAs, which is in line
with previous publications [48, 47]. A total of 96 %
cases were classified correctly using only this single
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parameter. The probability of an APA increases by a
factor of 5.2 per percentage point of Ki67 immunoreac-
tive nuclei (p < 0.001). A strong connection between Ki-
67 LI, proliferation and relapse status of adenomas was
confirmed in a recently published case-control study (n =
410) analyzing a post-surgical follow-up period of eight
years [49]. In this and several follow-up studies by the
same authors, a classification system for PA was proposed
according to tumor size, type and a specific grade newly
introduced [50, 51]. Although this data requires further
verification by other groups and is currently not yet part
of the WHO classification, it may represent a better ana-
lytical option for clinicians making decisions regarding the
appropriate therapeutic management.
Invasive pituitary adenomas were described as being
more aggressive in biological behavior and showing an in-
creased growth rate compared to that of non-invasive tu-
mors [36, 48, 52]. However, more than 47 % (n = 68/145)
of the TPAs in our cohort showed an invasive growth pat-
tern, a finding that is in line with several other observa-
tions published before (Table 3) [53, 6]. A low specificity
(53 %) reflects the fact that invasive growth is not limited
to the group of APA. According to our results, invasive-
ness was the least effective parameter for differentiating
between both adenoma subtypes. It showed an especially
broad confidence range (3.66; 18.42) [54]. Within both
subgroups, only 64 % of the invasive adenomas were clas-
sified correctly. On the other hand, invasive growth re-
mains a decisive prognostic factor in predicting patients’
disease-free status and overall outcome [49, 25]. This was
not the subject of the present study due to incomplete
follow-up data.
In order to describe additional criteria for the diagnosis
of an APA, we analyzed the expression patterns of the
alpha-subunit of glycoproteins (α-subunit) and the S-100
protein in the two subgroups. Both values (α-subunit
p = 0.955; S-100 p = 0.269) were not helpful in the dif-
ferential diagnosis and there were no significant dif-
ferences between both subgroups (LRA). However, we
found a significant correlation concerning the exist-
ence or absence of visible nucleoli and the correct
diagnosis. Therefore, nucleoli are related significantly
to the diagnosis of TPA (p = 0.008; OR = 0.4), a result
which is contrary to other tumor entities like men-
ingiomas [55, 5].
The diagnosis of APAs was introduced to describe a
possible precursor lesion for pituitary carcinomas (PCAs),
the only primary malignant tumor entity arising in the
sellar region [56]. An early diagnosis of PCA is essential
as the prognosis is usually poor (survival rate <1 year)
[57, 58]. Due to the fact that PCA have no known his-
tomorphological hallmarks, the diagnosis is still based
on detectable metastases [59–64, 56]. To elucidate
whether one or a combination of KI67 LI, p53
expression, invasive tumor growth and mitotic index
are helpful in the diagnosis, 10 PCA cases were in-
cluded in the study. All PCAs showed an invasive
growth pattern. In combination with an elevated Ki-67
LI (Accuracy: 86 %; Specificity: 93 %), these are good
prognostic markers for PCAs, as was previously sug-
gested in other studies [58, 65–67, 48]. Absence of in-
vasiveness in slowly growing TPAs largely reduces the
likelihood of PCA development because it was already
shown that PCAs do not develop a priori, but rather
through malignant transformations of TPAs in the major-
ity of cases [39, 65, 58].
A strong nuclear p53 expression was also a reliable
(Accuracy: 86 %) and specific single marker (Specifi-
city: 93 %) like Ki67 for PCAs and may explain their
aggressive biological behavior [29, 68]. Interestingly
enough, no mutations of the p53 gene were found in
PCAs [56, 69, 70]. The OR for p53 (p = 0.01) of 1.8 is
just as high as that of Ki-67 LI (p = 0.012), meaning
that the growth rate is a very important characteristic
in the analysis of clinical behavior, giving clinicians vital
clues about aggressive tumors that are difficult to treat
[48]. Only the mitotic index failed to demonstrate signifi-
cant difference between the group of PCA and both other
subtypes (LRA: p = 0.124; Point-biserial: p = 0.097). Des-
pite these results, it must be noted that 6 PCA specimens
(60 %) could not be reevaluated with respect to the num-
ber of mitoses. Therefore, the diagnostic relevance of the
mitotic index should not be disregarded as irrelevant, es-
pecially due to its sensitivity rate of 100 %. Other studies
confirmed this with similar findings of increased mitotic
indices in progressive and metastasized tumors [71–73].
Comparing APAs and PCAs, there were no significant
differences in LRA between the two groups with re-
gard to Ki-67 Li (p = 0.223), p53 (p = 0.585), mitotic
index (p = 0.274) and invasiveness (p > 0.999). Therefore,
metastases remain the only reliable sign indicating PCAs
(Tables 2 and 3) [59–64, 56].
An accurate classification of APAs is especially im-
portant so that an early diagnosis can be followed up
with the best-possible therapy for the patients (careful
watch, surgery, radiotherapy, medication, chemother-
apy) [74–76]. With the cut-off values demonstrated
here, a more precise categorization of adenomas in
terms of their Ki-67, p53, mitotic rate and invasive-
ness values may be possible. In addition, the cut-off
values also simplify the pathological analysis of aden-
omas in standard procedure, making the important
comparison of various case study groups possible
[77]. A prerequisite for this new opportunity, how-
ever, is that this method for diagnosing APAs is regu-
larly applied across the board [24] so that clinical
follow-up studies featuring large cohorts of APAs can
be performed. Such studies would make it possible to
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further investigate whether the cell behavior correlates
with the original diagnosis in terms of aggressiveness,
proliferation, recurrence rate and the disease-free,
post-surgery period. The clinical data sets of this
study, which are to be further analyzed in a follow-up,
provide the basis for additional studies of this kind.
Conclusion
The newly defined cut-off values of the mitotic index
(≥2) and p53 (≥2 %) makes the diagnosis of atypical ad-
enomas (APAs) more reliable than was the case in the
past. It is now possible to classify APAs in a standard-
ized, more uniform manner. This, in turn, greatly in-
creases the interrater reliability and also makes a direct
comparison with similar studies much simpler. In
addition, the accurate classification of APAs allows fur-
ther studies including clinical follow up data to test the
applicability or non- applicability of such a diagnosis ac-
cording to treatment and/or prognostic values. Accord-
ing to this study, the best marker for differentiating
typical pituitary adenomas and APAs is a Ki-67 (MIB-1)
LI >4 % (Youden index: 0.92; AUC: 0.98).
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